Document is current
Any future updates will be listed below
-
Authors
Nishihara, Hideaki
Soldati, Sasha
Mossu, Adrien
Rosito, Maria
Rudolph, Henriette
Muller, William A.
Latorre, Daniela
Sallusto, Federica
Sospedra, Mireia
Martin, Roland
Ishikawa, Hiroshi
Tenenbaum, Tobias
Schroten, Horst
Gosselet, Fabien
Engelhardt, Britta http://orcid.org/0000-0003-3059-9846
-
Funding
Funding for this research was provided by:
Swiss National Science Foundation (CRSII3_154483)
Gottfried und Julia Bangerter-Rhyner-Stiftung
Swiss Multiple Sclerosis Society
European Committee for Treatment and Research in Multiple Sclerosis
Uehara Memorial Foundation
Germaine de Steel PHC program
Germaine de Steel PHC
- License Information
-
More Information
Article History
Received: 13 November 2019
Accepted: 19 December 2019
First Online: 3 February 2020
Ethics approval and consent to participate
: The French Ministry of Higher Education and Research approved the protocol regarding the use of human tissues and cells (CODECOH Number DC2011-1321). All patients gave their consents. For the usage of HIBCPP model, Approval was obtained by the local ethics committee of the Medical Faculty of Mannheim, Heidelberg University (2009-327N-MA). Human primary cell protocols were approved by the Swiss Federal Office of Public Health (authorisation N. A000197/2 to F. Sallusto). Informed consent from blood donors was approved by the local ethical committee (Comitato Etico Cantonale, ExternalRef removed, authorization n. CE3428).
: Not applicable.
: RM received unrestricted Grants from Biogen and Novartis, personal compensation for lecture or advisory board functions from Biogen, Merck, Novartis, Roche, Sanofi Aventis, Teva, Cell-Protect and Neuway. He is a co-founder and co-owner of Cellerys, a startup company of the University of Zurich. RM is co-inventor and patent holder on patents related to antigen-specific tolerization, treatment/vaccination of PML and the use of daclizumab as a treatment of multiple sclerosis. BE received a Grant from Biogen to study extended natalizumab dosing on T-cell migration into the CNS.
